Astellas Pharma, Inc. engages in the manufacture, marketing, and import/export of pharmaceuticals products in Japan. It primarily focuses on the development of products in the areas of urology, immunology and allergy, cardiovascular and diabetes, gastrointestinal and motor organs, infectious diseases, and central nervous system. The company’s products include Prograf, for the prevention and treatment of organ rejection after liver and kidney transplants; Protopic, for the treatment of atopic dermatitis; Adenoscan, a pharmacologic stress imaging agent; AmBisome, a systemic antifungal agent; Micafungin, an injectable antifungal agent; and Vaprisol, a treatment for euvolemic hyponatremia. Its products also include Lipitor, for the treatment of hypercholesterolemia; Gaster, for the treatment of peptic ulcers and gastritis; Harnal, for functional symptoms associated with benign prostatic hyperplasia; the hypnotic Myslee; Seroquel, an antipsychotic; Funguard, a candin antifungal agent; and Micardis, a long-acting angiotensin I receptor antagonist. In addition, the company markets Omnic/Omnic OCAS, for the treatment of the functional symptoms of benign prostatic hyperplasia; Vesicare, for overactive bladder disease and urinary incontinence; and Eligard, a treatment for advanced prostate cancer. It primarily operates in Japan, North America, Europe, and Asia. Astellas Pharma has collaborations with MerLion Pharmaceuticals Pte, Ltd. for the discovery of new drug candidates from natural substances; Theravance, Inc. for the development and commercialization of Theravance's investigational antibiotic, telavancin; and Kirin Brewery Co., Ltd. for developing and marketing a human anti-CD40 antagonistic monoclonal antibody worldwide. The company was founded in 1923 and is headquartered in Tokyo, Japan.